Glenmark partners with Pfizer to launch drug for atopic dermatitis treatment in India
India, Feb. 1 -- American pharmaceutical giant Pfizer and Mumbai-based Glenmark Pharmaceuticals have joined hands to launch abrocitinib, a first of its kind oral advanced systemic treatment for moderate-to-severe atopic dermatitis (AD), in India.
Developed by Pfizer, abrocitinib has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) in India and is approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.
When launched in India, it will be co-marketed under the brand names JABRYUS and CIBINQO by Glenmark and Pfizer respectively. Abrocitinib (CIBINQO) is available in over 35 markets globally, including the US, Japan, and China.
Atopic...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.